Gentian Diagnostics ASA (GENT.OL)
ValueMarkers Composite Index
74% below intrinsic value ($16)
Gentian Diagnostics ASA (GENT.OL) — VMCI valuation read
Composite valuation read on GENT.OL: VMCI 59/100 against a Healthcare sector median of 50. The 9-point above-median print is the headline number for Gentian Diagnostics ASA, and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.
Trailing 30-day insider activity for GENT.OL: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.
**Investor frame.** Value, quality, risk in three lines on GENT.OL: GENT.OL trades at 17.0x earnings, 6% below the Healthcare median of 18.0x; ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%); net debt to EBITDA of 0.6x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.
GENT.OL rose 2.3% over the trailing 7 days, with a +2.7% read on a 30-day basis.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.